Chi H, Jang JK, Kim JH, Vezina P (October 2006). „Blockade of group II metabotropic glutamate receptors in the nucleus accumbens produces hyperlocomotion in rats previously exposed to amphetamine”. Neuropharmacology51 (5): 986–92. DOI:10.1016/j.neuropharm.2006.06.008. PMID16901517.
Yoon HS, Jang JK, Kim JH (September 2008). „Blockade of group II metabotropic glutamate receptors produces hyper-locomotion in cocaine pre-exposed rats by interactions with dopamine receptors”. Neuropharmacology55 (4): 555–9. DOI:10.1016/j.neuropharm.2008.07.012. PMID18675831.
Sakagami K, Yasuhara A, Chaki S, et al. (April 2008). „Synthesis, in vitro pharmacology, and pharmacokinetic profiles of 2-[1-amino-1-carboxy-2-(9H-xanthen-9-yl)-ethyl]-1-fluorocyclopropanecarboxylic acid and its 6-heptyl ester, a potent mGluR2 antagonist”. Bioorg. Med. Chem.16 (8): 4359–66. DOI:10.1016/j.bmc.2008.02.066. PMID18348906.
Ornstein PL, Bleisch TJ, Arnold MB, Kennedy JH, Wright RA, Johnson BG, Tizzano JP, Helton DR, Kallman MJ, Schoepp DD, Hérin M. 2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability. Journal of Medicinal Chemistry. 1998 Jan 29;41(3):358-78. PMID9464367.
Kingston AE, Ornstein PL, Wright RA, Johnson BG, Mayne NG, Burnett JP, Belagaje R, Wu S, Schoepp DD. LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors. Neuropharmacology. 1998;37(1):1-12. PMID9680254.
Fitzjohn SM, Bortolotto ZA, Palmer MJ, Doherty AJ, Ornstein PL, Schoepp DD, Kingston AE, Lodge D, Collingridge GL. The potent mGlu receptor antagonist LY341495 identifies roles for both cloned and novel mGlu receptors in hippocampal synaptic plasticity. Neuropharmacology. 1998 Dec;37(12):1445-58. PMID9886667
Johnson BG, Wright RA, Arnold MB, Wheeler WJ, Ornstein PL, Schoepp DD. [3H]-LY341495 as a novel antagonist radioligand for group II metabotropic glutamate (mGlu) receptors: characterization of binding to membranes of mGlu receptor subtype expressing cells. Neuropharmacology. 1999 Oct;38(10):1519-29. PMID10530814.
Pilc A, Chaki S, Nowak G, Witkin JM. Mood disorders: regulation by metabotropic glutamate receptors. Biochemical Pharmacology. 2008 Mar 1;75(5):997-1006. PMID18164691
Matrisciano F, Panaccione I, Zusso M, Giusti P, Tatarelli R, Iacovelli L, Mathé AA, Gruber SH, Nicoletti F, Girardi P. Group-II metabotropic glutamate receptor ligands as adjunctive drugs in the treatment of depression: a new strategy to shorten the latency of antidepressant medication? Molecular Psychiatry. 2007 Aug;12(8):704-6. PMID17653204
Gewirtz JC, Marek GJ. Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors. Neuropsychopharmacology. 2000 Nov;23(5):569-76. PMID11027922
Benneyworth MA, Xiang Z, Smith RL, Garcia EE, Conn PJ, Sanders-Bush E. A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis. Molecular Pharmacology. 2007 Aug;72(2):477-84. PMID17526600
Fischer BD, Miller LL, Henry FE, Picker MJ, Dykstra LA. Increased efficacy of mu-opioid agonist-induced antinociception by metabotropic glutamate receptor antagonists in C57BL/6 mice: comparison with (-)-6-phosphonomethyl-deca-hydroisoquinoline-3-carboxylic acid (LY235959). Psychopharmacology (Berlin). 2008 Apr 8; PMID18392754
Fischer BD, Zimmerman EI, Picker MJ, Dykstra LA. Morphine in combination with metabotropic glutamate receptor antagonists on schedule-controlled responding and thermal nociception. Journal of Pharmacology and Experimental Therapeutics. 2008 Feb;324(2):732-9. PMID17982001
Chi H, Jang JK, Kim JH, Vezina P (October 2006). „Blockade of group II metabotropic glutamate receptors in the nucleus accumbens produces hyperlocomotion in rats previously exposed to amphetamine”. Neuropharmacology51 (5): 986–92. DOI:10.1016/j.neuropharm.2006.06.008. PMID16901517.
Yoon HS, Jang JK, Kim JH (September 2008). „Blockade of group II metabotropic glutamate receptors produces hyper-locomotion in cocaine pre-exposed rats by interactions with dopamine receptors”. Neuropharmacology55 (4): 555–9. DOI:10.1016/j.neuropharm.2008.07.012. PMID18675831.
Sakagami K, Yasuhara A, Chaki S, et al. (April 2008). „Synthesis, in vitro pharmacology, and pharmacokinetic profiles of 2-[1-amino-1-carboxy-2-(9H-xanthen-9-yl)-ethyl]-1-fluorocyclopropanecarboxylic acid and its 6-heptyl ester, a potent mGluR2 antagonist”. Bioorg. Med. Chem.16 (8): 4359–66. DOI:10.1016/j.bmc.2008.02.066. PMID18348906.
